HC Wainwright Issues Positive Outlook for TCRX Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities researchers at HC Wainwright boosted their Q1 2026 earnings per share (EPS) estimates for shares of TScan Therapeutics in a report released on Wednesday, March 4th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.17) per share for the quarter, up from their previous forecast of ($0.20). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.49) EPS.

Other equities research analysts have also recently issued reports about the stock. Morgan Stanley cut shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Thursday, January 22nd. Finally, Wedbush raised their target price on shares of TScan Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a research report on Thursday. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, TScan Therapeutics presently has an average rating of “Hold” and an average price target of $7.00.

TScan Therapeutics Trading Down 0.9%

Shares of TCRX stock opened at $1.12 on Friday. The company has a market capitalization of $63.56 million, a price-to-earnings ratio of -1.12 and a beta of 1.03. The company has a current ratio of 8.41, a quick ratio of 6.44 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average price of $1.06 and a 200 day moving average price of $1.39. TScan Therapeutics has a twelve month low of $0.88 and a twelve month high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.09. TScan Therapeutics had a negative return on equity of 79.36% and a negative net margin of 1,256.81%.The company had revenue of $2.57 million during the quarter.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TCRX. Catalyst Funds Management Pty Ltd acquired a new stake in shares of TScan Therapeutics in the second quarter worth approximately $26,000. Quadrature Capital Ltd purchased a new position in TScan Therapeutics during the second quarter worth approximately $33,000. Boothbay Fund Management LLC boosted its holdings in shares of TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in shares of TScan Therapeutics in the 4th quarter valued at $25,000. Finally, HRT Financial LP purchased a new stake in shares of TScan Therapeutics during the 4th quarter valued at $26,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were purchased at an average cost of $0.90 per share, with a total value of $72,062.10. Following the purchase, the insider owned 7,937,416 shares in the company, valued at approximately $7,143,674.40. This represents a 1.02% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders bought 161,801 shares of company stock worth $145,621 in the last quarter. Corporate insiders own 4.35% of the company’s stock.

TScan Therapeutics News Roundup

Here are the key news stories impacting TScan Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple 2026–2028 EPS forecasts (Q1–Q4 2026 and FY2026–FY2028), lifting FY2026 from ($0.88) to ($0.76) and improving several quarterly loss estimates — and reiterating a “Buy” rating with a $7 price target. The firm’s view reduces near‑term downside in estimates and provides a sizable upside reference point for investors. HC Wainwright research note
• Positive Sentiment: Wedbush raised its price target from $4.00 to $5.00 and maintained an Outperform rating — another independent price‑target lift that can attract investor interest given the stock’s current low base. Benzinga article
• Neutral Sentiment: HC Wainwright also published a FY2030 projection (EPS ≈ ($0.09)), extending visibility far into the future; long‑range estimates are informative but carry high uncertainty for a pre‑commercial/clinical‑stage biotech. HC Wainwright long‑term model
• Negative Sentiment: HC Wainwright slightly lowered its FY2029 EPS forecast (to ($0.49) from ($0.47)), a modest downgrade that highlights ongoing long‑term uncertainty; the company remains unprofitable and consensus EPS is still negative (≈ ($1.12) current full‑year estimate), keeping valuation tied to clinical progress and execution risk. HC Wainwright note

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.